- -

Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis

Show full item record

Gil-Raga, M.; Jantus-Lewintre, E.; Gallach-Garcia, S.; Giner-Bosch, V.; Frangi-Caregnato, AF.; Safont-Aguilera, MJ.; Garde-Noguera, J.... (2018). Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. Clinical & Translational Oncology. 20(11):1422-1429. https://doi.org/10.1007/s12094-018-1874-8

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/137018

Files in this item

Item Metadata

Title: Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis
Author: Gil-Raga, Mireia Jantus-Lewintre, Eloisa Gallach-Garcia, Sandra Giner-Bosch, Vicent Frangi-Caregnato, Alejandro Federico Safont-Aguilera, María José Garde-Noguera, Javier Zorraquino-Pina, Estefanía García-Martínez, Marisa Camps-Herrero, Carlos
UPV Unit: Universitat Politècnica de València. Departamento de Estadística e Investigación Operativa Aplicadas y Calidad - Departament d'Estadística i Investigació Operativa Aplicades i Qualitat
Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia
Issued date:
Abstract:
[EN] PurposeAfter surgical resection, an ample prognosis variability among stages is observed. Multiple prognostic factors are individually studied and some CRC classifiers have been proposed. Not one have been implemented ...[+]
Subjects: Colorectal cancer , Prognostic factor , Molecular subtypes
Copyrigths: Cerrado
Source:
Clinical & Translational Oncology. (issn: 1699-048X )
DOI: 10.1007/s12094-018-1874-8
Publisher:
Springer-Verlag
Publisher version: https://doi.org/10.1007/s12094-018-1874-8
Type: Artículo

References

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. No. 11 [Internet], vol. 11. Lyon: International Agency for Research on Cancer. 2013. p. http://globocan.iarc.fr .

Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med. 2009;362(13):1246 (author reply 1246–1247).

Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20(4):1043–8. [+]
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. No. 11 [Internet], vol. 11. Lyon: International Agency for Research on Cancer. 2013. p. http://globocan.iarc.fr .

Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med. 2009;362(13):1246 (author reply 1246–1247).

Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20(4):1043–8.

Rodríguez-Moranta F, Castells A, Andreu M, Piñol V, Castellvi-Bel S, Alenda C, et al. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol. 2006;101(5):1104–11.

Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol. 2006;24(15):2359–67.

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.

Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327(6120):293–7.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature [Internet]. 2002;417(6892):949–54.

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67(6):2643–8.

Seppälä TT, Böhm JP, Friman M, Lahtinen L, Väyrynen VMJ, Liipo TKE, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer [Internet]. 2015;112(12):1966–75.

Birgisson H, Edlund K, Wallin U, Påhlman L, Kultima H, Mayrhofer M, et al. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer [Internet]. 2015;15(1):125.

Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology [Internet]. 2015;148(1):88–99.

Osumi H, Shinozaki E, Suenaga M, Matsusaka S, Konishi T, Akiyoshi T, et al. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. Int J Cancer. 2016;139(4):803–11.

Edge T. AJCC Cancer Staging Handbook. From the AJCC cancer staging manual. 7th ed. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL TA, editor. New York: Springer; 2010.

Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–30.

Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–100.

Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med [Internet]. 2013;369(11):1023–34.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol [Internet]. 2015;26(1):13–21.

Hassabo HM, Sahin IH, Kazmi SMA, Al Mutar SS, Gomes DBD, Pini TM, et al. Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS). J Clin Oncol. 2014;32(3_suppl):473.

Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, et al. Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC):results from NCCTG Intergroup phase III Trial N0147. J Clin Oncol. 2010;28(18s).

Lee D-W, Kim KJ, Han S-W, Lee HJ, Rhee YY, Bae JM, et al. KRAS Mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol [Internet]. 2014;187–94.

Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, et al. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol. 2015;21(4):1275–83.

Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322–30.

Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.

Chen KH, Lin YL, Liau JY, Tsai JH, Tseng LH, Lin LI, et al. BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. Med Oncol. 2016;33(5).

Kakar S, Aksoy S, Burgart LJ, Smyrk TC. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol. 2004;17(6):696–700.

Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.

De Sousa E, Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LPMH, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med [Internet]. 2013;19(5):614–8.

Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med [Internet]. 2013;19(5):619–25.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.

Stintzing S, Wirapati P, Lenz H-J, Neureiter D, von Weikersthal LF, Decker T. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. J Clin Oncol. 2017; 35(15)_suppl:3510.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

Le DT, Durham JN, Smith KN, Wang Hao, Bartlett Bjarne R, Aulakh Laveet K, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.

Overman MJ, Lonardi S, Wong KYM, Lenz H-J, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair—deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9.

[-]

This item appears in the following Collection(s)

Show full item record